SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Hillstream BioPharma, Inc. (HILS) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 25/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — HILS
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.12
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.10 |
$0.00 |
$-1.17M |
- |
| 2020 |
$-0.21 |
$0.00 |
$-2.37M |
- |
| 2021 |
$-0.30 |
$0.00 |
$-3.04M |
- |
| 2022 |
$-0.75 |
$0.00 |
$-8.47M |
- |
| 2023 |
$-7.14 |
$0.00 |
$-9.32M |
- |
| 2024 |
$-9.41 |
$0.00 |
$-12.2M |
- |
| 2025 |
$-1.12 |
$0.00 |
$-35.92M |
- |
